Oct 30 (Reuters) - Bluebird bio (BLUE.O), opens new tab said on Monday it has agreed to sell its priority review voucher for $103 million if it gets the U.S. Food and Drug Administration's approval ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback